Evolution of Clinical Trials in Multiple Sclerosis

Overview

Journal Ther Adv Neurol Disord

Specialty Neurology

Date 2019 Mar 6

PMID 30833985

Citations 20

Authors

Yinan Zhang

Amber Salter

Erik Wallstrom

Gary Cutter

Olaf Stuve

Affiliations

Soon will be listed here.

Abstract

Clinical trials have advanced the treatment of multiple sclerosis (MS) by demonstrating the safety and efficacy of disease-modifying therapies (DMTs). This review discusses major changes to MS clinical trials in the era of DMTs. As treatment options for MS continue to increase, patients in modern MS trials present earlier and with milder disease compared with historic MS populations. While placebo-controlled trials for some questions may still be relevant, DMT trials in relapsing-remitting MS (RRMS) are no longer ethical. The replacement of the placebo arm by an active comparator arm in trials have raised the cost of trials by requiring larger sample sizes to detect on-study changes in treatment effects. Efforts to improve trial efficiency in RRMS have focused on exploring adaptive designs and relying on sensitive magnetic resonance imaging measures of disease activity. In trials for progressive forms of MS (PMS), the lack of sensitive outcome measures that can be used in shorter-term trials have delayed the development of effective treatments. Recent shifting of the focus to advancing trials in PMS has identified paraclinical outcome measurements with improved potential, and the testing of agents for neuroprotection and remyelination is in progress.

Citing Articles

Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion.

Filippi M, Amato M, Avolio C, Gallo P, Gasperini C, Inglese M J Neurol. 2025; 272(2):179.

PMID: 39891770 PMC: 11787267. DOI: 10.1007/s00415-025-12917-4.

MultiSCRIPT-Cycle 1-a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical....

Janiaud P, Zecca C, Salmen A, Benkert P, Schadelin S, Orleth A Trials. 2024; 25(1):607.

PMID: 39261900 PMC: 11391827. DOI: 10.1186/s13063-024-08454-6.

Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.

Pfeuffer S, Wolff S, Aslan D, Rolfes L, Korsen M, Pawlitzki M Neurology. 2024; 103(2):e209574.

PMID: 38870471 PMC: 11244741. DOI: 10.1212/WNL.0000000000209574.

Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.

Tramacere I, Virgili G, Perduca V, Lucenteforte E, Benedetti M, Capobussi M Cochrane Database Syst Rev. 2023; 11:CD012186.

PMID: 38032059 PMC: 10687854. DOI: 10.1002/14651858.CD012186.pub2.

A backpack-based myeloid cell therapy for multiple sclerosis.

Kapate N, Dunne M, Kumbhojkar N, Prakash S, Wang L, Graveline A Proc Natl Acad Sci U S A. 2023; 120(17):e2221535120.

PMID: 37075071 PMC: 10151518. DOI: 10.1073/pnas.2221535120.

References

Cutter G, Baier M, Rudick R, Cookfair D, Fischer J, Petkau J . Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999; 122 ( Pt 5):871-82. DOI: 10.1093/brain/122.5.871. View

Lublin F, Reingold S . Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Ann Neurol. 2001; 49(5):677-81. View

Emanuel E, Miller F . The ethics of placebo-controlled trials--a middle ground. N Engl J Med. 2001; 345(12):915-9. DOI: 10.1056/NEJM200109203451211. View

Dalton C, Brex P, Miszkiel K, Hickman S, MacManus D, Plant G . Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol. 2002; 52(1):47-53. DOI: 10.1002/ana.10240. View

Norgren N, Rosengren L, Stigbrand T . Elevated neurofilament levels in neurological diseases. Brain Res. 2003; 987(1):25-31. DOI: 10.1016/s0006-8993(03)03219-0. View

Andersen O, Elovaara I, Farkkila M, Hansen H, Mellgren S, Myhr K . Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004; 75(5):706-10. PMC: 1763573. DOI: 10.1136/jnnp.2003.010090. View

Miller J . The importance of early diagnosis of multiple sclerosis. J Manag Care Pharm. 2004; 10(3 Suppl B):S4-11. View

Fisher J, Jacobs D, Markowitz C, Galetta S, Volpe N, Nano-Schiavi M . Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology. 2006; 113(2):324-32. DOI: 10.1016/j.ophtha.2005.10.040. View

Polman C, OConnor P, Havrdova E, Hutchinson M, Kappos L, Miller D . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9):899-910. DOI: 10.1056/NEJMoa044397. View

10.

Drexler W, Fujimoto J . State-of-the-art retinal optical coherence tomography. Prog Retin Eye Res. 2007; 27(1):45-88. DOI: 10.1016/j.preteyeres.2007.07.005. View

11.

Polman C, Reingold S, Barkhof F, Calabresi P, Clanet M, Cohen J . Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology. 2008; 70(13 Pt 2):1134-40. DOI: 10.1212/01.wnl.0000306410.84794.4d. View

12.

Fisniku L, Chard D, Jackson J, Anderson V, Altmann D, Miszkiel K . Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol. 2008; 64(3):247-54. DOI: 10.1002/ana.21423. View

13.

Sormani M, Tintore M, Rovaris M, Rovira A, Vidal X, Bruzzi P . Will Rogers phenomenon in multiple sclerosis. Ann Neurol. 2008; 64(4):428-33. DOI: 10.1002/ana.21464. View

14.

Mikol D, Barkhof F, Chang P, Coyle P, Jeffery D, Schwid S . Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008; 7(10):903-14. DOI: 10.1016/S1474-4422(08)70200-X. View

15.

Thorpe K, Zwarenstein M, Oxman A, Treweek S, Furberg C, Altman D . A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009; 62(5):464-75. DOI: 10.1016/j.jclinepi.2008.12.011. View

16.

OConnor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D . 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009; 8(10):889-97. DOI: 10.1016/S1474-4422(09)70226-1. View

17.

Goodin D, Bates D . Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler. 2009; 15(10):1175-82. DOI: 10.1177/1352458509107007. View

18.

Conway D, Cohen J . Combination therapy in multiple sclerosis. Lancet Neurol. 2010; 9(3):299-308. DOI: 10.1016/S1474-4422(10)70007-7. View

19.

Rissin D, Kan C, Campbell T, Howes S, Fournier D, Song L . Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010; 28(6):595-9. PMC: 2919230. DOI: 10.1038/nbt.1641. View

20.

Speight J, Barendse S . FDA guidance on patient reported outcomes. BMJ. 2010; 340:c2921. DOI: 10.1136/bmj.c2921. View